BMS-986165
|
|
|
- CAS-Nr.
- 1609392-27-9
- Englisch Name:
- BMS-986165
- Synonyma:
- Deucravacitinib;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Tyk2-IN-4;Deucravacitinb;BMS-986165 API;BMS-986165, >98% (HPLC);Deucravacitinib (TYK2-IN-4;Deucravacitinib(BMS986165);TYK2-IN-4;BMS986165;BMS-986165;BMS 986165;DeucravacitinibQ: What is
Deucravacitinib Q: What is the CAS Number of
Deucravacitinib
- CBNumber:
- CB74808663
- Summenformel:
- C20H22N8O3
- Molgewicht:
- 422.45
- MOL-Datei:
- 1609392-27-9.mol
|
BMS-986165 Eigenschaften
- storage temp.
- Store at -20°C
- L?slichkeit
- DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
- Aggregatzustand
- A crystalline solid
- Farbe
- Off-white to light yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H372 |
Sch?digt bei Hautkontakt und Verschlucken die Organe bei l?ngerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
P260, P264, P270, P314, P501 |
|
| Sicherheit |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P314 |
Bei Unwohlsein ?rztlichen Rat einholen / ?rztliche Hilfe hinzuziehen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
BMS-986165 Chemische Eigenschaften,Einsatz,Produktion Methoden
Allgemeine Beschreibung
Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.
BMS-986165 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
BMS-986165 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 180)Lieferanten
- Tyk2-IN-4
- TYK2-IN-4;BMS986165;BMS-986165;BMS 986165
- Deucravacitinib(BMS986165)
- Deucravacitinib (TYK2-IN-4
- 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide
- DeucravacitinibQ: What is
Deucravacitinib Q: What is the CAS Number of
Deucravacitinib
- 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
- Deucravacitinib
- Janus kinase,inhibit,JAK,Interleukin Related,Interferon-alpha/beta receptor,BMS 986165,Interferon-α/β receptor,IFNAR,Inhibitor,Deucravacitinib,BMS986165
- 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamide
- 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
- Deucravacitinb
- BMS-986165 API
- BMS-986165, >98% (HPLC)
- 1609392-27-9
- API
- APIS
- API
